PMID- 37214450
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230523
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - The efficacy and mechanism of vonoprazan-containing triple therapy in the 
      eradication of Helicobacter pylori.
PG  - 1143969
LID - 10.3389/fphar.2023.1143969 [doi]
LID - 1143969
AB  - Purpose: Vonoprazan (VPZ) produces a strong acid-inhibitory effect, which can 
      potentially eradicate Helicobacter Pylori (H. pylori). We aimed to assess whether 
      a 14-day VPZ-containing triple therapy was safe and effective in the Chinese 
      population and the potential mechanism. Methods: Enrolled patients confirmed to 
      be infected with H. pylori were randomly divided into four groups: VPZ + 
      doxycycline + furazolidone, VPZ + doxycycline + amoxicillin, esomeprazole (EPZ) + 
      bismuth + doxycycline + furazolidone, and EPZ + colloidal bismuth + doxycycline + 
      amoxicillin for 14 days. The eradication rate, medication adherence, and 
      incidence of adverse events (AEs) were evaluated. Inhibition of H. pylori by VPZ 
      and EPZ in vitro was assessed. H. pylori treated with appropriate concentrations 
      of VPZ and EPZ were sequenced by transcriptome analysis to explore the 
      antibacterial mechanism. Results: A higher eradication rate were observed in 
      VPZ-containing triple therapy. No obvious differences were observed in medication 
      adherence or the incidence of AEs. VPZ had no direct inhibitory effect on H. 
      pylori, whereas EPZ directly inhibited H. pylori may through downregulated genes 
      related to the ribosome. Conclusion: In the Chinese population, 14-day 
      VPZ-containing triple therapy was safe and more effective and can be used 
      clinically as first-line H. pylori treatment. Clinical Trial Registration: 
      ClinicalTrials.gov, identifier NCT05097846.
CI  - Copyright (c) 2023 Zhang, Liu, Ai, Chen, Liu, Zhang, Fang, Fu, Wang and Tang.
FAU - Zhang, Zinan
AU  - Zhang Z
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
AD  - Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Liu, Fen
AU  - Liu F
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
AD  - Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Central South 
      University, Changsha, Hunan, China.
FAU - Ai, Feiyan
AU  - Ai F
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
AD  - Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Central South 
      University, Changsha, Hunan, China.
FAU - Chen, Xiong
AU  - Chen X
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Liu, Rui
AU  - Liu R
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Zhang, Chao
AU  - Zhang C
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Fang, Ning
AU  - Fang N
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Fu, Tian
AU  - Fu T
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Wang, Xiaoyan
AU  - Wang X
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
AD  - Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Central South 
      University, Changsha, Hunan, China.
FAU - Tang, Anliu
AU  - Tang A
AD  - Department of Gastroenterology, The Third Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
AD  - Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Central South 
      University, Changsha, Hunan, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT05097846
PT  - Journal Article
DEP - 20230505
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10196117
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - efficiency
OT  - eradication
OT  - safety
OT  - triple therapy
OT  - vonoprazan
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/05/22 19:11
MHDA- 2023/05/22 19:12
PMCR- 2023/05/05
CRDT- 2023/05/22 12:12
PHST- 2023/01/13 00:00 [received]
PHST- 2023/04/07 00:00 [accepted]
PHST- 2023/05/22 19:12 [medline]
PHST- 2023/05/22 19:11 [pubmed]
PHST- 2023/05/22 12:12 [entrez]
PHST- 2023/05/05 00:00 [pmc-release]
AID - 1143969 [pii]
AID - 10.3389/fphar.2023.1143969 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 May 5;14:1143969. doi: 10.3389/fphar.2023.1143969. 
      eCollection 2023.